BeOne Medicines (BEIGF) Cash from Operations Growth (1y) (2016 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) Cash from Operations Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.95 Bn | 625.20 Bn | 17.26 Bn | 122.18% |
| 2 | AbbVie | 441.39 Bn | 434.82 Bn | 12.70 Bn | -33.32% |
| 3 | Merck | 366.72 Bn | 359.58 Bn | 12.21 Bn | 63.07% |
| 4 | Novartis Ag | 266.68 Bn | 258.99 Bn | 11.24 Bn | -11.73% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 243.47% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 107.90% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.50 Bn | 20.96 Bn | 1.57 Bn | 1,034.67% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 63.59% |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 75.58% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 75.58% |
| Mar 31, 2026 | 356.73% |
| Dec 31, 2025 | 455.28% |
| Sep 30, 2025 | 113.70% |
| Jun 30, 2025 | 375.76% |
| Mar 31, 2025 | 114.29% |
| Dec 31, 2024 | 133.91% |
| Sep 30, 2024 | 341.04% |
| Jun 30, 2024 | 67.47% |
| Mar 31, 2024 | 45.27% |
| Dec 31, 2023 | 30.34% |
| Sep 30, 2023 | 86.09% |
| Jun 30, 2023 | 22.65% |
| Mar 31, 2023 | -138.32% |
| Dec 31, 2022 | 37.34% |
| Sep 30, 2022 | -13.35% |
| Jun 30, 2022 | 9.59% |
| Mar 31, 2022 | -289.11% |
| Dec 31, 2021 | -52.81% |
| Sep 30, 2021 | -43.17% |